PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 72.50
Bid: 60.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 25.00 (41.667%)
Open: 72.50
High: 72.50
Low: 72.50
Prev. Close: 72.50
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

7 Nov 2008 07:00

RNS Number : 6725H
Stanelco PLC
07 November 2008
 



7th November 2008

STANELCO PLC ("the Company" or "the Group")

Interim Management Statement

The Board of Stanelco Plc today issues its interim management statement for the nine month period ended 30 September 2008.

Overview

The first nine months of the year saw 120% growth in sales revenue to £12.2m compared with the same period last year (2007: £5.6m). We continued to make progress in reducing our operating losses.

Divisional Performance

BioPlastics

Commercialisation of the bioplastics technology continues as the Company broadens its base of regular customers, which is now developed across a variety of European markets.

Sales of bioplastics, made directly by Stanelcoare now up 450compared to the same 9 month period last year. Direct sales in the third quarter were up 24% on the second quarter, reaching £1.4m year-to-date.

In the third quarter the Company opened a small sales office in the USA to begin the process of exploiting the emerging opportunity for sustainable bioplastics in North America. This renewed activity is being driven by an experienced plastics industry professional and is already creating an encouraging pipeline of trials.

We have continued to strengthen the BioPlastics division in the UK by recruiting further senior technical and customer support expertise with substantive relevant expertise.  

Further minor investment in development and testing equipment was also made at the UK development facility in the period. Development trials continue to establish pace and laboratory success, with a number of new products having moved to pre-commercial trials with several customers.

RF Applications

In RF Applications divisionthe strong enquiry book is gradually being converted into orders and we expect to see some benefit of that in the second half as the General Manager and newly appointed Sales Manager begin to achieve traction.

The optical fiber furnace market continues to show encouraging signs, driven by continued fiber demand in Asia. In the third quarter, Stanelco continued to strengthen its position in China with its first order for its new generation of higher capacity furnaces powered by Stanelco's new RF generator.

There is also growing interest in the newly developed mobile welding products. However, the long lead times from enquiry to order mean that this is likely to have limited impact on this financial year's results.

Financial Position

We continue to maintain a strong balance sheet. Our cash position at 30 September was £6.9mstrengthened since the half year by working capital movements related to stock reduction.

Outlook 

Our strategy is clear and good progress is being made. We continue to look for compatible and sensible investment opportunities.

We remain alert to the rapidly changing economic conditions throughout the worldbut we have not seen an impact on our business as yet. The Board's expectations for the financial performance for 2008 remain in line with those set earlier in the year.

Ends -

Paul Mines, Chief Executive, Stanelco plc

Clive Warner, Finance Director, Stanelco plc

Tel: +44 (0) 2380 867 100

Jonathon Brill/Caroline Stewart

Financial Dynamics

Tel: +44 (0) 20 7831 3113

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBFBPTMMIMBBP
Date   Source Headline
17th Oct 200610:44 amRNSNotifiable Interest
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.